Litrozz (Letrozole 2.5 mg)

Litrozz (Letrozole 2.5 mg) is an aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. By blocking the aromatase enzyme Letrozole effectively reduces estrogen levels in the body which can slow the growth of estrogen-dependent tumors. Litrozz is often prescribed as an initial treatment or for patients experiencing recurrence making it a crucial component in the management of breast cancer and helping to improve patient outcomes.